Klein Management of Prostate Cancer

2. Auflage 2004
ISBN: 978-1-59259-776-5
Verlag: Humana Press
Format: PDF
Kopierschutz: 1 - PDF Watermark

E-Book, Englisch, 667 Seiten, eBook

Reihe: Current Clinical Urology

Although much progress has been made in the four years since the first edition of Management of Prostate Cancer, prostate cancer remains a significant biological, me- cal, and personal challenge for millions of men. In this interval, some important trends and observations have emerged that represent real progress in the field and which will shape the direction of clinical practice and research in the next 5–10 years. These obs- vations include: (1) a decline in prostate-related cancer mortality in the United States, likely owing to a combination of factors including screening, more aggressive and earlier therapy, and improvements in specific therapies; (2) a significant downward pathological stage migration, so that an individual’s chance of cure for a given stage, grade, and PSA is better now than it was early in the PSA era, even without associated improvements in individual therapies; (3) the recognition of new PSA isoforms that may refine screening strategies; (4) several randomized, phase III clinical trials demonstrating survival adv- tages of one form of therapy over another in selected populations (external beam rad- therapy with adjuvant hormones vs radiotherapy alone, radical prostatectomy vs observation); (5) a focus on the biology of bone and bone metastasis, and new agents that reduce skeletal-related events and which may inhibit the growth of new metastases; (6) second-generation anti-PSMA antibodies with improved potential for imaging and therapy; (7) the development and widespread adoption of nomograms that assist in cli- cal decision-making for individual patients; (8) the identification of new genes that

Zielgruppe

Professional/practitioner

Autoren/Hrsg.

Klein, Eric A.

Inhaltsverzeichnis

I. Screening, Risk Factors, Diagnosis, and Prevention.- 1 Prostate Cancer Overdiagnosis and Overtreatment: Analysis of US Mortality and SEER Incidence Trends in the PSA and Pre-PSA Eras.- 2 Total, Complexed, and Free PSA Forms and Human Glandular Kallikrein 2: Clinical Application for Early Detection and Staging of Prostate Cancer.- 3 Defining an Optimum PSA-Based Screening Strategy for Young Men.- 4 Hereditary Prostate Cancer and Genetic Risk.- 5 Strategies for the Chemoprevention of Prostate Cancer.- 6 The Special Problems of Prostate Cancer Among African Americans: Clinical and Molecular Factors.- 7 Current Issues in Pathologic Evaluation.- 8 Current Trends in Biopsy Techniques.- II. Localized Disease: Treatment and Outcomes.- 9 Predicting Outcomes: Artificial Neural Networks and Nomograms.- 10 When Is Observation Appropriate?.- 11 Contemporary Technique of Radical Prostatectomy: Open Approach.- 12 Contemporary Technique of Radical Prostatectomy: Laparoscopic Approach.- 13 Contemporary Technique of Radical Prostatectomy: Perineal Approach.- 14 Anesthetic Considerations for Contemporary Radical Prostatectomy.- 15 Conformal External Beam Radiotherapy.- 16 Brachytherapy.- 17 Androgen Deprivation and Radiation Therapy for Localized Prostate Cancer.- 18 Prostate Brachytherapy: The Role of Supplemental External Beam Radiotherapy.- 19 Health-Related Quality of Life Issues.- 20 The Evaluation and Management of Postprostatectomy Urinary Incontinence.- 21 Sural Nerve Grafting During Radical Prostatectomy: Techniques and Results.- 22 Management of Erectile Dysfunction Following Radical Prostatectomy.- 23 Counseling Patients With Localized Prostate Cancer: Radiation or Surgery?.- 24 Counseling the Patient With Prostate Cancer: The Radiation Oncologist’s Perspective.- 25Counseling Patients on Choice of Therapy: The Medical Oncologist’s Perspective.- 26 Emotional and Informational Support for the Patient Undergoing Radical Prostatectomy.- 27 Prostate Cancer: A Survivor’s View.- 28 Prostate Cancer: A Spouse’s View.- III. Advanced Disease.- 29 Management of PSA Recurrence After Definitive Therapy for Prostate Cancer.- 30 When to Refer a Patient With Prostate Cancer to a Medical Oncologist: The Earlier the Better.- 31 Management of Newly Diagnosed Metastatic Disease.- 32 Management of the Patient With Androgen-Independent Metastatic Prostate Cancer.- 33 Bone-Targeted Therapy for Prostate Cancer.- IV. Applied Molecular Biology.- 34 Biology of PSMA As a Diagnostic and Therapeutic Target.- 35 Opportunities for Targeted Molecular Therapy for Prostate Cancer.